193 related articles for article (PubMed ID: 7016323)
1. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
3. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
[TBL] [Abstract][Full Text] [Related]
4. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
7. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
14. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
Crilley P; Lazarus H; Topolsky D; Ciobanu N; Creger RJ; Fox RM; Bulova SI; Shina DC; Gucalp R; Cooper BW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):50-4; quiz 55. PubMed ID: 8342076
[TBL] [Abstract][Full Text] [Related]
15. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
Van Echo DA; Wiernik PH; Aisner J
Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA
Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
[TBL] [Abstract][Full Text] [Related]
17. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
[TBL] [Abstract][Full Text] [Related]
18. High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
Vellekoop L; Jagannath S; Spitzer G; Zander AR; Horwitz LJ; Keating M; McCredie KB; Dicke KA
Am J Clin Oncol; 1986 Aug; 9(4):307-10. PubMed ID: 3529919
[TBL] [Abstract][Full Text] [Related]
19. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide/etoposide: effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse.
Kalwinsky DK; Dahl GV; Mirro J; Look AT
Cancer Treat Rep; 1985; 69(7-8):887-9. PubMed ID: 4016796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
